

TRAVERE & MCPHS BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP



TRAVERE[®]
THERAPEUTICS

Global Medical Affairs

WHO WE ARE


Traverse Therapeutics is determined to bring life-changing treatments, support, and hope to people with rare disease.

At Traverse Therapeutics, we are in rare for life

We come together every day to help patients, families, and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop, and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.




At the center of all we do is our culture and our four corporate values:



**We are
patient-inspired**



**We are
courageous**



**We promote
community**



**We are stronger
together**

Advancing the pipeline

We are impatient for the patients we serve



We are driven to deliver safe and effective therapies to patients as quickly as possible. To do this, we are advancing a pipeline of potential first-in-class medicines targeting rare diseases with significant unmet needs. Traverre announced full FDA approval of a therapy for **IgA nephropathy**, a rare kidney disease (RKD) that is a leading cause of kidney failure due to glomerular disease. We are in late-stage clinical development for a treatment for **focal segmental glomerulosclerosis** (FSGS), an RKD with no approved treatments. We are evaluating what could potentially become the first disease-modifying therapy for people living with **classical homocystinuria**.

Fellowship program overview

The Traverre Global Medical Information/Medical Affairs Fellowship Program is a highly specialized postgraduate training experience designed to provide pharmacy school graduates with hands-on mentorship and professional growth. Through direct collaboration with experienced preceptors, the fellow will gain a deep understanding of how medical affairs contributes to organizational strategy, scientific excellence, and meaningful patient outcomes. This program offers the opportunity to develop expertise in medical information and cross-functional partnership, while reinforcing Traverre's commitment to professional development, innovation, and advancing care in rare diseases.

This fellowship is a 2-year program with a primary focus on global medical information. This program will also include rotations across various teams within global medical affairs:

- Field Medical
- Scientific Communications
- Strategic Management & Excellence
- Digital Engagement & Innovation
- Training & Governance

The program may also include rotation(s) aligned with the fellow's interest and company need. For more information, please contact medical.information@traverse.com.

Program Directors/Preceptors



**Alexandra Willcockson,
Ph.D.**

Associate Director,
Global Medical Information



**Hiren Patel,
Pharm.D.**

Senior Director,
Global Medical Information
and Governance



**Jerry Lieu,
Pharm.D.**

Director,
Global Medical Information

MCPHS BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP



Eligibility

The MCPHS Biopharmaceutical Industry fellows will be selected on a nationally competitive basis.

- Applicants must have a doctor of pharmacy degree from an ACPE-accredited college of pharmacy at the commencement of the program.
- Candidates must have strong written and verbal communication skills and a strong interest in pursuing a career within the biopharmaceutical industry.
- All candidates must have authorization to work in the United States throughout the duration of the 1- or 2-year fellowship. No visa sponsorship will be provided (i.e. TN, H-1B, STEM OPT, etc.).



Boston, MA

MCPHS BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP

Application procedure

The MCPHS application portal (SMAApply) will open on **Monday, October 6, 2025**. Applicants must upload the following application materials to the online portal (mcphs.smapply.io) by **Monday, November 3, 2025**:

- Letter of intent (addressed to the Traverre program directors)
- Curriculum vitae
- Unofficial college transcript
- Contact information for three references. References will receive an electronic recommendation form to complete separately.

Three recommendation evaluation forms must be submitted no later than **Monday, November 20, 2025** via the online portal. This is NOT a letter of recommendation but an online form that the recommender will receive for completion from SMAApply.

Application review and interview timeline

Following a review of submitted applications, pre-screens and preliminary interviews will begin in **October**. Additional interviews, including final rounds, will take place in **December** during ASHP. Candidates will be notified if selected for an interview. The process is rigorous and competitive; therefore, candidates should submit their applications well in advance of posted deadlines as priority will be given to those who apply early.

ASHP midyear and onsite interviews

MCPHS BIOPHARMACEUTICAL INDUSTRY FELLOWSHIP

The following information from ASHP and AIFA is provided to assist with understanding important deadlines and process steps.

ASHP midyear and onsite interviews

The fellowship program will be conducting in-person interviews at the ASHP Midyear Clinical Meeting in Las Vegas, NV, **December 7-10, 2025**. Attendance is strongly encouraged, but not required. Candidates attending in person will not be able to interview without registering for both [ASHP](#) and [PPS](#).



Top candidates may be invited to interview virtually or at Traverre's headquarters.

AIFA first offer date

The choice of a post-doctoral fellowship is an important decision. MCPHS, in conjunction with the Alliance of Industry Fellowship Associates (AIFA), has aligned to extend offers for fellowships no earlier than **Friday, December 12, 2025**. We believe this is a positive reflection of the cultures our programs offer, and that culture is a critical consideration in choice of fellowship.

We hope that other academic and non-academic fellowship programs will NOT pressure candidates to accept offers prior to this aligned offer date.

Onboarding

Final candidates will be required to go through additional screening and onboarding as required by MCPHS.



TRAVERE[®]
THERAPEUTICS

Global Medical Affairs